DYN at a glance
Dyne Therapeutics, Inc. (DYN, SEC CIK 1818794) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 29, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Dyne Therapeutics, Inc. (DYN) shares worth $1.4 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Posner Brian S on October 2, 2026 of 2,500 shares at $16.00 per share.
- In the last 90 days, DYN insiders reported 1 open-market purchase ($40K) and 17 open-market sales ($72.3M) on Form 4, a net sale of $72.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 1 buy · 17 sells
- Net −$72.3M
- 13F holders
- 31 funds
- $1.4B · +2 vs prior quarter
- Latest 8-K
- Sep 29, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development of product candidates for rare muscle diseases, leveraging manufacturing agreements with CMOs
- New master manufacturing services agreements in 2025 securing $169.9M total fees committed through 2027 for product candidate components
- Strategic emphasis on formalizing manufacturing capacity to support clinical and production scalability versus prior informal agreements
- Notable R&D investment: $31.2M paid towards non-current assets under manufacturing agreement as of Dec 31, 2025, with additional $109.5M committed
- Lease agreement for office and lab space with 8.5-year term started Sept 2021, with monthly rent increasing to $0.5M during term
Risk Factors
- FDA clinical hold on z-rostudirsen IND in Jan 2022, delaying trial start until July 2022 clearance
- Geopolitical and market risk from clinical and regulatory approval uncertainty in US and EU (FDA, EMA) regulatory agencies
- Supply chain vulnerability in establishing manufacturing for Fab antibody, linker, therapeutic payload components for clinical and commercial supply
- Competitive risk from delayed commercialization of product candidates until at least 2027, risking losing market share to established biotech peers
- Financial risk from $1.4B accumulated deficit with net losses of $446.2M in 2025 and $317.4M in 2024, reliant on $1.1B cash runway to Q1 2028 and $275M Hercules loan facility with restrictive covenants
Management Discussion & Analysis
- No profitability or margin figures provided, expenses expected to increase with ongoing activities
- No segment financial data; primary emphasis on research and development of multiple product candidates
- Cash, cash equivalents, marketable securities sufficient to fund operations into Q1 2028
- Capital needs to be met via equity, debt, collaborations, with risk of dilution and restrictive covenants; risk of delayed development if funding unmet
AI summary of the DYN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales generated
- Net loss $178.6M vs $110.9M YoY; operating loss $181.7M vs $115.8M
- R&D expense $152.2M vs $99.2M; z-rostudirsen highest program at $52.3M
- July offering generated approximately $405.0M net proceeds; funding expected into Q2 2028
- Potential z-rostudirsen U.S. launch Q1 2027; tariffs may increase supply-chain costs and delay development
Risk Factors
- Newly triggered financing risk: July 2026 offering added approximately $405.0 million net proceeds but may deplete sooner than expected
- Most material update: Hercules Loan Agreement amended in June 2026, adding third-tranche borrowing and new covenant exposure
- Debt compliance risk: Minimum Cash Covenant begins July 1, 2027 at 40% of outstanding obligations when market capitalization is below $1.65 billion
- Regulatory risk: FDA clinical holds or additional preclinical requests could delay trials, as occurred with z-rostudirsen before July 2022 clearance
- Near-term development risk: Product candidates remain preclinical or clinical, with commercialization not expected until at least 2027, if ever
AI summary of the DYN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Additional one-year MAD data for DYNE-101 in the Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1
- Mean baseline video hand-opening time disclosed for ACHIEVE registrational expansion cohort participants
Item EX-99.1: Item EX-99.1
- One-year Phase 1/2 data strengthen z-basivarsen’s efficacy case across myotonia, function, strength and patient-reported outcomes
- vHOT improved 3.2 seconds at 6 months versus 0.4-second worsening on placebo, a 3.6-second relative benefit
Item 8.01: Other Events
- One-year pooled ACHIEVE data showed sustained improvements in myotonia, function, strength and patient-reported outcomes
- vHOT improved 3.2 seconds at six months versus 0.4-second worsening for placebo, a 3.6-second relative improvement
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results covered quarter ended June 30, 2026
- Press release issued July 29, 2026 and furnished as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- FDA accepted z-rostudirsen’s DMD BLA with Priority Review; PDUFA action date January 21, 2027, supporting potential Q1 2027 launch
- ACHIEVE enrollment completed at 71 participants; topline z-basivarsen data planned Q1 2027, supporting potential accelerated-approval filing in Q3 2027
Item 1.01: Entry into a Material Definitive Agreement
- $375.2M gross equity offering from 18.3M shares at $20.50 per share
- Approximately $352.1M net proceeds, increasing to $405.0M if the 2.745M-share option is fully exercised
Item 8.01: Other Events
- Public offering pricing announced July 21, 2026; transaction details reside in Exhibit 99.1
- Offering proceeds plus existing liquidity and $50.0M Hercules term-loan tranche expected to fund operations through second quarter 2028
Item EX-99.1: Item EX-99.1
- $375.15M gross proceeds from 18.3M shares priced at $20.50 each
- Potential additional $56.27M proceeds from underwriters’ 2.745M-share, 30-day option
AI summaries of DYN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DYN
Don't miss the next DYN filing
- Alerts as it files. A push when DYN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DYN, by share count.
- Ask anything. An AI agent that reads every DYN filing and answers with sources.
DYN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Posner Brian S | Buy | Oct 2, 2026 | 2,500 | $16.00 |
| Kerr Douglas | Sell | Sep 8, 2026 | 1,290 | $18.88 |
| Friedl-Naderer Johanna | Sell | Sep 8, 2026 | 185 | $18.88 |
| Cox John | Sell | Sep 8, 2026 | 5,658 | $18.88 |
| Friedl-Naderer Johanna | Sell | Sep 4, 2026 | 900 | $24.35 |
| Kerr Douglas | Sell | Sep 4, 2026 | 3,745 | $24.35 |
| Rhodes Jason P | Sell | Aug 14, 2026 | 322,465 | $25.00 |
| Rhodes Jason P | Sell | Aug 14, 2026 | 478,377 | $25.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$242.2M | -$343.9M | -$468.2M |
| Net Income | - | -$317.4M | -$446.2M |
| Balance Sheet | |||
| Total Assets | $165.1M | $691.2M | $1.2B |
| Equity | $91.3M | $629.8M | $972.1M |
| ROE | - | -50.4% | -45.9% |
| Per Share | |||
| EPS | $-3.95 | $-3.37 | $-3.47 |
| Cash Flow | |||
| Operating CF | -$188.2M | -$292.4M | -$403.2M |
| CapEx | $729K | $2.4M | $1.9M |
Source: XBRL data in Dyne Therapeutics, Inc. (DYN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate DYN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $1.40B |
| Q1 2026 | 29 | $980.6M |
| Q4 2025 | 23 | $1.00B |
| Q3 2025 | 25 | $634.8M |
| Q2 2025 | 24 | $359.6M |
| Q1 2025 | 21 | $288.8M |
| Q4 2024 | 17 | $576.4M |
| Q3 2024 | 16 | $348.3M |
- FMR LLC (Fidelity)+2.30M (+26%)
- T. Rowe Price Group+1.61M (+69%)
- Dimensional Fund Advisors+994.9K (+105%)
- Citadel Advisors LLC+942.8K (+469%)
- State Street Corp+804.5K (+12%)
- Morgan Stanley−182.8K (-20%)
- Renaissance Technologies LLC−173.0K (-32%)
- Vanguard Portfolio Management LLC−113.6K (-3%)
- JPMorgan Chase & Co−101.8K (-3%)
- Vanguard Capital Management LLC−94.1K (-1%)
- D.E. Shaw & Co+60.2K
- Two Sigma Investments+14.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DYN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 29, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
DYN SEC filings: frequently asked questions
Are DYN insiders buying or selling?
In the last 90 days, Dyne Therapeutics, Inc. (DYN) officers, directors and 10% owners reported 1 open-market purchase worth $40,000 by 1 insider and 17 open-market sales worth $72.3 million by 6 insiders on Form 4, a net sale of $72.3 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DYN stock?
As of June 30, 2026, the largest Dyne Therapeutics, Inc. (DYN) holders among the 13F filers tracked by SignalX were BlackRock ($275.5 million), FMR LLC (Fidelity) ($248.9 million), State Street Corp ($165.6 million), Vanguard Capital Management LLC ($140.2 million), Vanguard Portfolio Management LLC ($89.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in DYN's latest 10-K?
In the 10-K filed March 2, 2026, Dyne Therapeutics, Inc. (DYN) flagged: FDA clinical hold on z-rostudirsen IND in Jan 2022, delaying trial start until July 2022 clearance. Geopolitical and market risk from clinical and regulatory approval uncertainty in US and EU (FDA, EMA) regulatory agencies. (AI summary of the Risk Factors section.)
What did DYN report in its latest 8-K?
Dyne Therapeutics, Inc. (DYN) filed an 8-K on September 29, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Additional one-year MAD data for DYNE-101 in the Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1.
What are the latest DYN SEC filings?
Dyne Therapeutics, Inc. (DYN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on September 29, 2026 and a Form 4 insider filing on October 6, 2026.
What is DYN's SEC CIK number?
Dyne Therapeutics, Inc. (DYN)'s SEC Central Index Key (CIK) is 1818794. EDGAR lists every DYN filing under that number.
Ask anything about DYN
The research agent reads DYN's filings, financials, insider trades and 13F holders, then answers with sources.